British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders

…, H Selsick, AL Sharpley, AG Wade - Journal of …, 2010 - journals.sagepub.com
Sleep disorders are common in the general population and even more so in clinical practice,
yet are relatively poorly understood by doctors and other health care practitioners. These …

The client in psychotherapy

AC Bohart, AG Wade - Bergin and Garfield's handbook of …, 2013 - books.google.com
In recent years there has been a shift toward greater recognition of the client’s role as an
active participant in psychotherapy. In 1994 Bergin and Garfield said,“Another important …

Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes

AG Wade, I Ford, G Crawford… - … medical research and …, 2007 - Taylor & Francis
Objective: Melatonin, the hormone produced nocturnally by the pineal gland, serves as a
circadian time cue and sleep-anticipating signal in humans. With age, melatonin production …

Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter …

AG Wade, M Farmer, G Harari, N Fund… - … interventions in aging, 2014 - Taylor & Francis
Purpose A link between poor sleep quality and Alzheimer’s disease (AD) has recently been
suggested. Since endogenous melatonin levels are already reduced at preclinical AD stages…

[HTML][HTML] Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous …

AG Wade, I Ford, G Crawford, A McConnachie, T Nir… - BMC medicine, 2010 - Springer
Background Melatonin is extensively used in the USA in a non-regulated manner for sleep
disorders. Prolonged release melatonin (PRM) is licensed in Europe and other countries for …

The effect of citalopram in panic disorder

AG Wade, U Lepola, HJ Koponen… - The British journal of …, 1997 - cambridge.org
BackgroundCitalopram is a serotonin reuptake inhibitor which has been demonstrated to be
highly selective and with a superior tolerability profile to the classical tricyclic …

Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short-and long-term response

AG Wade, G Crawford, I Ford… - … medical research and …, 2011 - Taylor & Francis
Objectives: The authors recently reported on efficacy and safety of prolonged-release
melatonin formulation (PRM; Circadin 2 mg) in elderly insomnia patients. The age cut-off for …

The societal costs of insomnia

AG Wade - Neuropsychiatric disease and treatment, 2010 - Taylor & Francis
Objective Insomnia can be broadly defined as difficulty initiating or maintaining sleep, or sleep
that is not refreshing or of poor quality with negative effect on daytime function. Insomnia …

A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder

UM Lepola, AG Wade, EV Leinonen… - Journal of Clinical …, 1998 - psychiatrist.com
Background: The objective of this study was to evaluate the efficacy and tolerability of
citalopram in the long-term treatment of adult outpatients with panic disorder with or without …

Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy

…, FA Mahnert, F Rouillon, AG Wade… - The British Journal of …, 2001 - cambridge.org
BackgroundMajor depression is highly recurrent. Antidepressant maintenance treatment has
proven efficacy against recurrent depression.AimsComparison of prophylactic efficacy of …